Indeed, studies have demonstrated that BCR-ABL mutants are present at the time of diagnosis in many ALL patients, and as sequencing technologies improve, smaller and smaller subclones with resistant phenotypes will likely be discovered [29]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.